Jan 22, 2010: Aurgalys-CLS issues new BioAlliance analyst note [EuroNext: BIO.FP] on a very promising 2010 outlook
janvier 22, 2010
Through our analysis we considered that for BioAlliance:
- Major milestones were met in 2009
- Two products are due to be launched in new markets
- Five products currently in clinical development including one which has completed phase III
We recommand a BUY for the stocks with a target price of €12 within one year
Download our BioAlliance Coverage here (available in english only)